argenx SE
(FRA:1AE)
€
808.4
+51 (+6.73%)
Market Cap: 49.86 Bil
Enterprise Value: 45.36 Bil
PE Ratio: 41.27
PB Ratio: 7.89
GF Score: 78/100 argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021 / 06:10PM GMT
Release Date Price:
€217.4
(+2.94%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Hi, good afternoon, everyone. Apologies for the technical delays, but welcome to the originally scheduled 2:10 session at the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover both U.S. and European biopharma names here at the firm. It's my great pleasure to be hosting argenx today in a fireside chat. And with me, I'd like to welcome the company CEO, Tim Van Hauwermeiren; COO, Keith Woods; and Karl Gubitz, who was announced a week ago as the company's new CFO.
So with that, I want to welcome the 3 of you, and thank you for your participation.
Timothy Van Hauwermeiren
argenx SE - CEO & Executive Director
Thank you, Graig.
Questions & Answers
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
So for those who might be somewhat new to the argenx story, although
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot